Annual Miles Matching Week That Doubles the Value of Donated Miles to Help Sick Children is Now Open
Until December 8, Aeroplan Miles donated to the Air Canada Foundation will be matched to help transport sick children for medical care they need away from home
Attn. video editors: See how the Air Canada Foundation's Hospital Transportation Program makes a difference in the lives of sick children needing to travel for medical care through Beckett's story: https://youtu.be/hOpbr5q51TU
MONTREAL, Dec. 3, 2019 /CNW Telbec/ - The annual Aeroplan Miles Matching week in support of the Air Canada Foundation Hospital Transportation Program, which helps sick children travel to obtain specialized medial care, is now underway. Until December 8, 2019, members who donate Aeroplan miles to the Air Canada Foundation Hospital Transportation Program will double the impact of their contribution with all miles donated to be matched, up to 500,000 miles.
The Air Canada Foundation Hospital Transportation Program helps children like Beckett, a fearless Saskatchewan-born 2.5 year old, who was diagnosed at two months old with infant acute lymphoblastic leukemia, an extremely rare disese that affects only eight children in Canada each year. Following his initial nine month treatment in Toronto, Beckett needed to return for a series of follow-up specialist appointments that could not be facilitated in his home community.
"Beckett has had 807 doses of chemo, 16 surgeries, 31 blood transfusions, and spent 189 days in hospital. We had to, and still have to, travel and to have the Hospital Transportation program in place to get him to where he needs to be is the greatest gift," said Beckett's mom, Kelley.
"Each and every mile donated to the Air Canada Foundation has the power to significantly impact the lives of children and their family in this country. The ability of the Hospital Transportation Program to help children like Beckett travel for specialized medical care is made possible and attainable through the support of generous Aeroplan members," said Priscille LeBlanc, Chair of the Air Canada Foundation. "The Air Canada Foundation donates each year on average close to 10 million Aeroplan Miles to 15 pediatric hospitals across Canada which, in turn, provide flights to children who need specialized health care that is not available in their hometown."
"Any time a child and family is travelling to Shriners Hospitals for Children for assessment or surgery, as Shriners we do our utmost to diminish their stress by providing food, lodging and transportation. The Air Canada Foundation Hospital Transportation Program allows us to fly more children to the hospital and this makes a big difference in the lives of hundreds of families," said Wayne Cormier, Transportation Chairman Luxor Shriners at Shriners Hospitals for Children.
The Aeroplan Miles Matching Week in support of the Air Canada Foundation Hospital Transportation Program is on now and runs through Sunday, Dec. 8, 2019. To donate your Aeroplan Miles, please visit aircanada.com/Foundation and select the "Donate" button located on the top banner or visit the Aeroplan Donation Program on the Air Canada Foundation page.
About the Air Canada Foundation
The Air Canada Foundation, a not-for-profit organization focused on the health and well-being of children and youth, was launched in 2012. It offers both financial and in-kind support to Canadian registered charities. Core programs include the Hospital Transportation Program, which donates Aeroplan Miles to 15 pediatric hospitals across Canada, enabling sick children to access the medical care they need but which are unavailable locally. The Air Canada Foundation, in collaboration with the airline, also engages directly in fundraising activities, such as the Every Bit Counts program, which encourages Air Canada and Air Canada Rouge customers to donate loose change of all denominations aboard flights or through collection containers available in Air Canada Maple Leaf Lounges. The Foundation also offers continued support to major health-related causes that benefit Canadians and is an active participant in international humanitarian relief activity as the need arises. For more information about the Air Canada Foundation, please visit www.aircanada.com/foundation or the 2018 Corporate Sustainability Report, Citizens of the World, online at www.aircanada.com/citizensoftheworld.
Avicanna's Rho Phyto Branded Products to be Available in California
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./
TORONTO, Dec. 1, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) today announces that LC2019, Inc. ("LC2019"), the entity that holds a license to Avicanna's intellectual property in the United States, has advised Avicanna that it has entered into an agreement (the "License Agreement") with a subsidiary of Kings Garden Inc. ("Kings Garden"), a California based company, manufacturing the Kings Garden brand, with extensive experience in the cultivation, processing and manufacturing of high-end cannabis products, pursuant to which LC2019 will sub-license Avicanna's Rho PhytoTM brand and proprietary formulations (collectively, the "Rho Products") to Kings Garden.
As announced by Avicanna in its November 26, 2019 press release, Avicanna has an option to acquire all of the outstanding shares of LC2019, which option may be exercised by Avicanna at any time and is expected to be exercised upon cannabis cultivation, processing, distribution and possession becoming federally legal in the United States.
Under the terms of the License Agreement, LC2019, through a wholly-owned subsidiary, has provided the Kings Garden team with an exclusive license to use the Rho Phyto trademark and to manufacture, market, distribute and sell the Rho Phyto advanced formulation products in the State of California. In consideration of the license granted under the License Agreement, the Kings Garden team has agreed to pay to LC2019 a royalty equal to 40% of the net profits from the sale of the Rho Products. Kings Garden, through its licensed subsidiary, will produce, manufacture and sell the Rho Products in the State of California. The initial term of the License Agreement is three years.
"We are thrilled to see the Rho Phyto brand and advanced cannabis product offerings have their initial launch in the State of California which represents the largest and one of the most sophisticated consumer markets in the world. We are also excited that the LC2019 team has decided to partner with the Kings Garden team which have demonstrated industry leading products, quality and execution. We hope that this launch in California will provide the Rho Phyto brand with a foothold in the US market place, help establish a leading global brand and attain both market information and efficacy data around the proprietary product lines," stated Aras Azadian, Chief Executive Officer of Avicanna.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the timing of the exercise by Avicanna of its option to acquire all of the shares of LC2019 and the successful commercialization of the Rho Products in California. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
MIGHTY SELF LAUNCHES NEW CBD-BASED NEUTRACEUTICAL
SAN FRANCISCO, CALIF. (2020)—This year, Mighty Self, a health and wellness company that creates science-backed products formulated to help people sustain and enhance mental and physical health by harnessing the power of cannabinoids is launching BALANCE, a nutraceutical product that is designed to support the human body’s natural inflammatory response as well as help calm nervous tension. BALANCE is formulated with full-spectrum whole plant hemp-based CBD extract in combination with complimentary bioactive and apoptogenic herbs that assist in the body’s processes to boost mood, calm the mind, and relieve nervous tension. Made from specially selected domestic hemp, BALANCE is non-intoxicating and contains less than .03% THC (as mandated by the federal requirements of the 2018 Farm Bill).
Research for the product was based on studies that have found that the endocannabinoid system is made up of a network of receptor sites on cell membranes throughout the body. These cannabinoids behave as chemical activators that fit into those sites (CB1 & CB2). CB1 receptors are found predominately in the brain and central nervous system, and CB2 receptors in immune system cells and, to a lesser extent, in the brain.
Key ingredients in BALANCE include:CBD—CBD is a non-psychoactive compound found in the female cannabis plant that increases the levels of a naturally occurring cannabinoid in the brain called anadamide, which helps to regulate serotonin and dopamine, the neurotransmitters that trigger emotions. Preliminary studies have shown CBD to support a healthy inflammatory response, promote a feeling of relaxation, and maintain nervous system function in the body.Phenethylamine (PEA)—PEA is an organic compound that is found in foods like chocolate, beans and nuts that acts as a neurotransmitter in the body and has been shown to support focus and clarity, and promote a mood of wellbeing. Science has revealed that these results are due to the ability of PEA to reduce uptake and increase efflux of serotonin, dopamine and norepinephrine in the body.Hordenine—Hordenine is an alkaloid that naturally occurs in many plant foods (particularly barley). It has been suggested that hordenine may promote energy and focus due to its adrenergic properties, which cause nerve cells to release the neurotransmitters epinephrine and norepinephrine.DL-Phenylalanine (DLPA)—DLPA is a combination of D- and L- isomers of the amino acid phenylalanine. Phenylalanine can be converted into tyrosine, which is used to synthesize dopamine, epinephrine and norepinephrine, which can support mental alertness and focus when the body is under stressful conditions.Ashwagandha—Ashwagandha is an ayurvedic herb that has been used as an adaptogen for restoring physical and mental energy, especially when under daily stress. The ingredient has been shown to balance cortisol levels by mimicking the inhibitory neurotransmitter GABA. It has also been studied for its immune-activating effect and nootropic potential.Theobromine—Theobromine is a flavanol antioxidant compound found in the cacao bean which stimulates the nervous system with effects similar to caffeine. Studies have shown that the compound can increase mental function in older adults and has the ability to act on brain neurotransmitters to improve mood and increase energy.Curcumin—Curcumin is a compound found in turmeric. It is one of the most extensively investigated compounds of natural origin with many studies validating its role in promoting a healthy inflammatory response, antioxidant activity, and cell protection. Neurological tissue is particularly susceptible to oxidative stress, and curcumin has been shown to inhibit expression of COX-2 enzymes in the body’s inflammatory process. Mighty Self Balance is non-psychoactive, contains no artificial flavors, is sugar free and each bottle contains 25 capsules (suggested usage is one capsule per day). It is available at a retail price of $39.95 atmightycbd.co, where you can find more information about the brand.###About Mighty Self Mighty Self is a bioceutical company that creates science-based products formulated to help people sustain and enhance mental and physical health by harnessing the power of cannabinoids combined with other biologically active ingredients. As part of its adherence to ethical standards dedicated to increased wellbeing and health consciousness, the brand communicates with consumers under a policy of full transparency regarding ingredients used in its formulations and the sustainability of its processes in the development and manufacture of its products. The brand’s motto is “Health is the new wealth.” And every effort that is undertaken by Mighty Self is intended to contribute to a culture of increased health consciousness and personal improvement in the lives of everyone.
(These statements have not been evaluated by the Food and Drug Administration. Mighty Self products are not intended to medically diagnose, treat, cure, or prevent any disease.)
A self-repair guide for common holiday setbacks
Whether you’re panic shopping, bloated from too much partying, trying to maintain your holiday stamina, or struggling to get off the couch, the common cure is, always, exercise.
Gareth Nock, national team training specialist with GoodLife Fitness says just a bit of time spent moving can boost energy, improve your self-confidence and help alleviate stress when you most need it. Here are some self-repair workout tips and ideas to help you bypass common holiday health setbacks.
Bloated from the buffet A steady diet of cocktails and canapes can leave you feeling full, puffy and uncomfortable – mostly from water retention. The key is to drink lots of water and fit in cardio workout moves to sweat out the toxins. Exercise helps your body use excess water and shifts a lot of water into your muscles, which can reduce the puffy look and feel caused by retaining water.
Try some cardio. Jump on the elliptical for 30 minutes or enjoy a bike ride or a brisk walk to get sweating and sped up digestion. Yoga moves like a torso twist, elongated triangle, sphinx and cat-cow are also good to work muscles and get your gut working normally again, as well as reduce puffiness.
Not enough sleep Back-to-back holiday parties, late nights spent wrapping, plus shopping, holiday concerts, cooking and more can leave you exhausted. Unfortunately, it feels like there’s never enough time to sleep during the holiday countdown. It seems counterintuitive, but when you’re tired exercise is a great solution. Research shows people who complain of fatigue could increase their energy by 20 percent and decrease fatigue by as much as 65 percent by simply participating in regular low-intensity exercise.
Some great workouts for when you’re tired include incline walking or a light jog, pilates, dynamic stretching, or a group fitness class that will boost energy and morale.
Feeling the pressure It’s the most wonderful time of the year, but for many, the pressures of the holidays can be stressful. Family visits, battling crowds at shopping malls, filling an endless ‘to do’ list can take away your Holiday Zen.
Working out is a perfect way to vent negative energy and minimize the effects of stress. When you exercise, your body reduces stress hormones like cortisol and increases the production of feel-good hormones (endorphins). A good workout can clear your mind and gets the blood flowing. It improves sleep and helps with digestion. Deep breathing, stretching, yoga, or a cardio session can make all the difference. Lifting weights for some strength training moves can help you vent extra stress energy.
Lost your motivation For many people, the holidays prompt the urge to lounge on the couch....sometimes for days. The longer you leave it, the more difficult it is to return to the gym. The key is to remind yourself of the benefits. Exercise can help increase your energy and decrease your appetite. There is a sense of accomplishment during the holiday season. You look better and your confidence increases.
The best exercises to boost motivation and energy are ones you enjoy. Try something new, like martial arts or a dance-inspired fitness class. Or get outside and enjoy skating, hiking or a run. Plan your workout around potential wins and set achievable goals to stay motivated.
You need a healthy party glow – right NOW Feeling a bit wilted after work? Try fitting in a quick workout at the gym or even at your desk to get your second wind and hit the town. For a quick sweat-free sculpting workout, try squats, lunges, planks, tricep dips and push-ups to improve posture, muscle tone and get your glow on.
Finding time to visit with friends Instead of hitting the pub for nachos, consider meeting up for a run or hitting a yoga class together. The opportunity to catch up while exercising is a productive way to use your time together. You’ll be able to challenge and motivate each other while benefiting from the feel-good endorphins that happen when you sweat together.
Not sure how to start your fitness resolutions? Instead of waiting for after the new year to re-start your fitness routine, why not use the extra time over the holidays to get a head start? Build in some gym time while work and routine are slower. It’s better to gradually increase your activity so you’re already underway when January 1 hits.
TORONTO, Nov. 29, 2019 /CNW/ - Canada Health Infoway (Infoway) and EndoSoft LLC (EndoSoft) announced today that the EndoVault v3.x solution has achieved Infoway certification under the 2017 Edition of pre-implementation certification requirements.
"We congratulate EndoSoft for achieving Infoway Certification as an ambulatory electronic medical record (aEMR), approved for deployment at customer sites," said Mark Nenadovic, Senior Director, Programs & Alliances, Infoway. "This achievement ensures that the company's solution conforms to the national and international standards for privacy and security."
EndoSoft's offering, EndoVault, is a market leading EMR solution developed with more than 25 years of expertise. EndoSoft is dedicated to enhancing interoperability and improving patient care through its applications.
"EndoSoft is proud that EndoVault 3.x has achieved Infoway Certification for our ambulatory EMR," said Rakesh K Madan, President & CEO, EndoSoft. "It highlights our commitment to ensuring that we meet the highest standards for all of our health care solutions, including standards for privacy and security."
Infoway Certification provides assurance that digital health software complies with specified requirements and standards, which helps ensure the protection of personal health information. The 2017 Edition requirements build upon Infoway's original certification requirements and are harmonized to increase alignment between Infoway, provincial requirements and international standards, and to reduce testing redundancies.
About EndoSoft
From a solo provider's practice to large multi-specialty hospital systems, EndoSoft applications are used by more than 50,000 clinical users worldwide and the company has become one of the most trusted names in healthcare technology.EndoSoft's offerings include EndoVault, a market leading EMR that boasts a multitude of specialties including Gastroenterology Endoscopy, ENT, OB/GYN, Pathology, Orthopedics, Cardiology, Pain Management, Pulmonology, Oncology, Ophthalmology, Dermatology and Urology, just to name a few along with modules for Nursing, Infusion, scheduling and inventory management. EndoVault is also compliant with multiple international standards including meaningful use and IHE. Visit www.endosoft.com.
About Canada Health Infoway
Infoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients and clinicians. Infoway is an independent, not-for-profit organization funded by the federal government. Visit www.infoway.ca.
L’Oréal Paris calls on Canadians to nominate extraordinary women for the 2020 Women of Worth Grant Award Program
For the fourth consecutive year, $110,000 in charitable grants will be presented on International Women’s Day to 10 Canadian women who are making a beautiful difference in their communities and the world
TORONTO, ON – L’Oréal Paris Canadatoday announced submissions for the Canadian edition of the 2020 Women of Worth Grand Award Program are open now through January 5, 2020 at http://womenofworth.ca/en.
Proudly entering its fourth year, the signature philanthropic initiative honours a diverse group of trailblazing Canadian women. The awards shine a spotlight on extraordinary women who selflessly volunteer their time to serve their communities and make a positive impact on the lives of others. Now through January 5, 2020 all Canadians are encouraged to nominate women who demonstrate commitment and leadership, make significant contributions across a breadth of causes and important initiatives and strive to create a more beautiful and accepting world for everyone.
“These remarkable Canadian innovators possess unrelenting drive, passion and commitment and inspire us by their generosity and selflessness for the crucial causes they champion,” said Milan Mladjenovic, General Manager, L’Oréal Paris Canada. “Every year, we are deeply moved by the personal motivations of the honourees and the beautiful impact their accomplishments continue to make to the lives of others and our world. These women show tremendous heart in all that they do, and we are humbled by their spirit and achievements.”
The nominees will be judged on four distinct criteria: addressing a crucial need in the community; the impact their inspiring contributions have made; their innovation on developing solutions; and their passion to evoke change and inspire future generations. The 10 select women will each receive a $10,000 donation to their non-profit cause and the chance to be recognized as a L’Oréal Paris Women of Worth honouree – joining an esteemed alumni of women who continue to make a tremendous impact in their communities. Additionally, the 10 honourees will receive an all-expense paid trip for two to Toronto to attend the notable, star-studded awards gala hosted by L’Oréal Paris on March 8, 2020, coinciding with International Women’s Day.
“I am extremely honoured to be part of the L’Oréal Paris Women of Worth alumni. As a small grassroots organization, it is difficult to receive the exposure you need to advocate for your cause,” said Lynne Rosychuk, 2019 Women of Worth Canada National Honouree. “As a result of being named the National Woman of Worth Honouree, our organization – The Jessica Martel Memorial Foundation - has gained global recognition and been acknowledged in the House of Commons by our MP, Dane Lloyd. We have also received many donations and support from new volunteers. It is difficult to talk about domestic violence and I truly appreciate the opportunity L’Oréal Paris gave me to platform the important work we are doing”.
The innovations of past award recipients have resulted in significant advancements in supporting Canadian families struggling with food insecurity; providing means for families to break free of domestic violence; increasing accessibility of cultural and tourist services for those living with limited physical abilities; evolving the preservation and protection of our environment and lifting socio-economic barriers of access to menstrual products for Northern Indigenous communities.
“How can one not feel inspired after seeing the astounding difference a few people can make to effect real change in their communities and beyond,” said Aja Naomi King, L’Oréal Paris Ambassador.
Aja Naomi King and the 2019 Women of Worth Honourees. Photo credit: L’Oréal Paris c/o Ryan Emberley In February 2020, the 10 nominees will be announced, and Canadians will have the opportunity to vote for a National Honouree to be awarded an additional $10,000 grant for her non-profit cause. At that time, the public can visit www.WomenofWorth.ca to read more details about each Honouree’s inspirational cause. Voters can cast one online vote per email address, each day until March 4th. These votes will be a contributing factor in the judging panel’s selection of the 2020 National Honouree.
To learn more about past Canadian Honourees, or to nominate a woman making a difference, please visit womenofworth.ca. About L’Oréal Paris L’Oréal Paris, the world’s no.1 beauty brand, is dedicated to empowering women and men by offering the most luxurious and innovative products and services available in the mass market. For most, the name “L’Oréal” is immediately evocative of the brand’s signature phrase, “Because I’m Worth It.”— the tagline behind the legendary advertising campaign for the Superior Preference® hair colour launch in 1973. Today, it represents the essence of the L’Oréal Paris brand as a whole, a spirit which is about helping every woman – and man - embrace their unique beauty while reinforcing their inner sense of self-worth. For more than 100 years, L’Oréal Paris has held an unparalleled commitment to advancement in technology, innovation and research, providing ground-breaking, high-quality products for women, men, and children of all ages and ethnicities in five major beauty categories: cosmetics, skincare, hair color, haircare, and men’s grooming.
First New Retinoid Molecule Approved in Over 20 Years
Next-generation retinoid, AKLIEF® trifarotene cream 50 mcg/g is proven effective in both facial and truncal acne treatment
THORNHILL, ON, Nov. 28, 2019 /CNW/ - Galderma, a global leader focused on meeting the world's increasing skin health needs, announced today that Health Canada approved AKLIEF® trifarotene cream, 50 mcg/g (AKLIEF) for the topical treatment of acne of the face and/or trunk in patients 12 years of age and older.
AKLIEF is the first new retinoid molecule to receive Health Canada approval for the treatment of acne in more than 20 years.1, 2, 3, 4 It is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.5,6,7 Also, AKLIEF is the first topical treatment specifically studied and proven to treat both facial (forehead, cheeks, nose and chin) and truncal (chest, shoulders and back) acne, offering healthcare professionals and Canadian acne patients another treatment option.3
"This new approval marks an important milestone in effectively treating acne in Canada, especially truncal acne," says Dr. Melinda Gooderham, a dermatologist and Medical Director at the SKiN Centre for Dermatology and the SKiN Research Centre in Peterborough, Ontario. "This next generation retinoid is exciting news for physicians and patients. The clinical evidence demonstrates that AKLIEF reduces inflammatory lesions on the face, back and chest while delivering low systemic levels. This ensures efficacy, safety and tolerability which makes AKLIEF particularly useful for the treatment of acne lesions that appear on large surfaces of the skin, like the back and chest of some acne patients."
About the Phase III Clinical Trials The Health Canada approval of AKLIEF is supported by data from the two pivotal Phase 3 clinical trials of once-daily AKLIEF in patients with moderate acne on the face and trunk.3 The two identical 12-week, randomized, multicenter, parallel group, double-blind, vehicle-controlled clinical trials of 2,420 patients showed that AKLIEF significantly reduced inflammatory lesions as early as two weeks on the face and four weeks on the back, shoulders and chest compared to vehicle (p<0.05).3 AKLIEF was well tolerated when used on the face, back, shoulders and chest.3
"The approval of AKLIEF is consistent with our intent to change the paradigm of how even the most common and frustrating skin diseases are treated, including acne," said Thibaud Portal PhD, Galderma Global Vice President, Prescription. "We are pleased to add this new treatment option, with proven efficacy in facial and truncal acne, to our innovative and differentiated portfolio of acne treatments."
AKLIEF is expected to be available in Canada in January 2020 by prescription only. It will be provided in a 75 gram pump.
About Acne Acne is the most common skin disease in Canada, affecting up to 5.6 million Canadians annually and approximately 80 per cent of young people.8 It occurs when pores become clogged by dead skin cells resulting in accumulation of sebum, an oily substance produced by oil glands.7 Bacteria within pores, called Cutibacterium acnes (C. acnes), can contribute to pore blockage and inflammation – visible as redness, swelling and pus that may accompany acne spots.7 Acne on the face is the most common and often the most visible presentation of the disease. More than half of people with facial acne (52 per cent) also have truncal acne.9 Adult acne tends to affect women more often than men and adult-onset acne is becoming increasingly common in women in their 20s and beyond.10 "Back acne" was once thought to be a predominantly male disease, has been shown to be prevalent in females.7,8,9,11 Acne can trigger feelings of depression, poor body image and low self-esteem.7,10
About AKLIEF® trifarotene cream, 50mcg/g3AKLIEF is a retinoid indicated for the topical treatment of acne vulgaris of the face and/or trunk in patients 12 years of age and older.
The full AKLIEF Cream Product Monograph for Canada is available here.
About Galderma Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. Galderma is a leader in the research and development of scientifically-defined and medically-proven solutions for the skin. Partnering with health care practitioners around the world to meet the skin health needs of people throughout their lifetime, the company aims to change the way the world thinks about skin health. For more information, please visit www.galderma.ca.
References
_________________________________
1
British Association of Dermatologists. Topical trifarotene: a new retinoid. Br J Dermatol. 2018;179:231-232.
Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, et al. Randomized Phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019. DOI: https://doi.org/10.1016/j.jaad.2019.02.044.
6
Aubert J, Piwnica D, Bertino B, Blanchet-Réthoré S, Carlavan I, et al. Nonclinical and human pharmacology of potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179:442-456.
7
Fisher GJ, et al. J Biol Chem 1994;269(32):20629-35.
Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846-850
SOURCE Galderma Canada
Joint declaration of the tripartite visit to Cameroon
JOINT FINAL DECLARATION OF THE TRIPARTITE VISIT OF THE CHAIRPERSON OF THE AU COMMISSION AND THE SECRETARIES GENERAL OF THE COMMONWEALTH AND THE OIF28 November 2019For immediate releaseThe Chairperson of the African Union Commission, Moussa Faki Mahamat, the Secretary-General of the International Organization of la Francophonie, Louise Mushikiwabo and the Secretary General of the Commonwealth, Patricia Scotland, undertook a tripartite visit to Yaoundé, Cameroon, from 26 to 28 November 2019, in order to exchange views with the national actors on the situation in Cameroon. The tripartite mission is an extension of the visits that the leaders of the above-mentioned organizations had undertaken over the last months to Cameroon. The aim of the tripartite mission was to encourage the ongoing national efforts for the implementation of the conclusions of the Grand National Dialogue, and support the pacification of the situation, peace-building, national cohesion and unity in this important country, which is a member of the three organizations.
The tripartite mission held talks with the President of the Republic, His Excellency Paul BIYA and the Prime Minister, Joseph Dion Ngute. It also met with the main political actors, religious leaders, youth representatives and other Civil Society Organizations. The Chairperson of African Union Commission, the Secretaries General of the OIF and Commonwealth welcomed the convening of the Grand National Dialogue which ushered in a new dynamic and which recommended, inter alia, the acceleration of decentralization, the special status of the North West and South West regions, and the review of the education and legal systems, including the measures taken by President Biya to defuse political tensions. Convinced that dialogue remains the preferred path to be encouraged within the present Cameroonian context, they encouraged all the stakeholders to continue on the path of wisdom and responsibility, particularly that of the government in the implementation of the conclusions of the Grand National Dialogue. The Chairperson of the AU Commission and the Secretaries General reaffirmed their commitment to support the national actors in the quest for ways and means to reach the necessary national political consensus, and the creation of conditions conducive to the conduct of legislative and local elections, particularly in the North West and South West regions of the country, in peace, national unity and in accordance with our shared democratic values. The three leaders also urged for every effort to be made in order to restore security, justice and the conditions for the resumption of normal life in the regions affected by the crisis.
REGINA, Nov. 28, 2019 /CNW/ - Lumeca Health, one of Canada's leading virtual healthcare platforms, is proud to announce the appointment of Leah Olson-Friesen to the role of Chief Operating Officer. With extensive management experience spanning over two decades, Olson-Friesen brings valuable leadership to Lumeca's executive team during a period of hyper-growth. As COO, Olson-Friesen will lead the company's finance and operational functions.
"Leah joins Lumeca with a wealth of management experience at both early-stage tech start-ups and mid-sized companies," said Shawn Hazen, Lumeca's founder & CEO. "We are thrilled to have a steady hand at the operational helm as we continue to expand our healthcare platform and broaden our customer base globally."
Prior to joining Lumeca, Olson-Friesen built and lead high performing teams in the private and public sectors across Canada. Olson-Friesen was CEO of DOT Technology Corp and CEO of SeedMaster Manufacturing. Beyond operations and finance management, she was responsible for all aspects of strategic planning, product development and customer service. Prior to the aforementioned, Olson-Friesen held successive positions as President of the Agricultural Manufacturers of Canada and Marketing and Communications Lead for Pfizer Canada. She is a board member of Ag West Bio and Intelliconn.
"Lumeca is experiencing accelerated growth with the success of its existing virtual healthcare platform and its planned expansion providing its virtual hospital unit (VHU) pilot program," said Olson-Friesen. "I am very excited to join Shawn who is an experienced entrepreneur and look forward to helping people who are looking for efficient and timely means to access healthcare services that meet their unique needs."
Olson-Friesen was recently nominated as one of Concordia University's top 50 under 50 shaping business for her leadership in technology and entrepreneurship. Olson-Friesen holds an MBA in Finance from Queens' University and a master's degree in Public Policy and Public Administration from Concordia University. Olson-Friesen is an avid runner and level II nationally certified rugby coach.
About Lumeca Health
Lumeca Health, one of Canada's leading virtual healthcare platforms, offering integrated healthcare services that connects people to our team of doctors, specialists, mental health professionals and hospitals 24/7.
Lumeca serves some of the world's leading employers, insurers, hospitals, pharmacies and healthcare systems while continually innovating healthcare access and improving outcomes making high-quality, patient-friendly healthcare a reality. Founded in 2016, Lumeca Health is proudly headquartered in Regina, Saskatchewan.
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD(1)
BURLINGTON, ON, Nov. 27, 2019 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved OFEV® (nintedanib) as the first and only treatment indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).2 Interstitial lung disease (ILD) is the leading cause of death related to systemic sclerosis (SSc) or scleroderma, accounting for 35 per cent of all disease-related deaths.3 This new approval changes the treatment paradigm for SSc-ILD, giving patients an opportunity to slow the progression of decline in lung function where no Health Canada approved options previously existed.
"Medical advancements, like the approval of OFEV®, are a rare thing when it comes to treating conditions like systemic sclerosis," said Dr. Martin Kolb, Respirologist at St. Joseph's Healthcare Hamilton and Director, Division of Respirology at McMaster University. "We now have the unprecedented opportunity to care for our patients in a different way that offers hope by slowing down the progression of this disease."
Systemic sclerosis is a rare disease estimated to affect up to 40,000 Canadians.4 Interstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma.5 Because scleroderma affects the connective tissue, symptoms can occur in any area of the body including the skin, muscles, blood vessels and internal organs, making it difficult to diagnose.6, 7, 8 More than 80 per cent of patients are women between the ages of 30 to 50.9
"When systemic sclerosis involves the lungs, it can be incredibly debilitating. For years I've watched my patients' disease progress and have been frustrated by the fact that there weren't any approved treatments to slow the disease from progressing," said Dr. Sindhu Johnson, Director of the Toronto Scleroderma Program and Associate Professor of Medicine at the University of Toronto. "I am excited to now be able to offer patients OFEV, which, by slowing the deterioration (or worsening) of the lungs, can help patients to continue to live well despite their disease."
OFEV® is currently approved in Canada and more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF), and has been shown to slow IPF progression by reducing the annual rate of decline in lung function, as measured by forced vital capacity (FVC).10 Both IPF and SSc-ILD are conditions known as pulmonary fibrosis, which is when the lungs become scarred and stiff.11
"With OFEV® being the first therapy available in Canada to slow the rate of decline in pulmonary function for patients with SSc-ILD, it provides hope for these patients and their loved ones," said Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. "This approval is supported by positive evidence from the Phase III SENSCIS study that showed that OFEV significantly slowed the progression of lung disease in this patient population."
The SENSCIS® Trial The approval was based on results of SENSCIS®, a Phase III double-blind randomized, placebo-controlled trial, that involved 576 patients across 32 countries, including Canada. The primary endpoint was the annual rate of decline in FVC in patients with SSc-ILD.12 Results show that OFEV® slowed the loss of pulmonary function by 44% (41 mL/year) in patients with SSc-ILD relative to placebo, as measured by FVC over 52 weeks.13
Results also showed the safety and tolerability of OFEV® in SSc-ILD patients. The most common adverse events (occurring in greater than or equal to 3%) in OFEV®-treated patients compared to placebo included: diarrhea, nausea, vomiting, abdominal pain, liver enzyme elevation, weight decreased, fatigue, decreased appetite, pneumonia, musculoskeletal pain, dizziness and hypertension.14
Both the FDA and Health Canada have granted approval for the application of nintedanib in SSc-ILD. This approval is a part of the company's ongoing commitment to improving the lives of people living with SSc-ILD.
Boehringer Ingelheim (Canada) Ltd. Improving the health of humans and animals is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.
_________________ 1 Ofev® Product Monograph. Boehringer Ingelheim (Canada) Ltd. November 21, 2019. 2 Ofev® Product Monograph. Boehringer Ingelheim (Canada) Ltd. November 21, 2019. 3 Silver KC, Silver RM. Management of Systemic Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am. 2015 Aug; 41(3): 439–457. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515778/ 4 Scleroderma Society of Canada. Scleroderma Overview. Available at https://fhs.mcmaster.ca/purr/documents/Scleroderma-Overview.pdf 5 Tyndall AJ et al. "Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database." Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. 6 Denton, CP, Khanna D. Systemic Sclerosis. Lancet 2017; 390: 1685-99. 7 Cottin V, et al. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir. Res. 2019;20(1):13. 8 US National Library of Medicine. Systemic Scleroderma. Available at: https://ghr.nlm.nih.gov/condition/systemic-scleroderma#genes 9 Scleroderma Society of Canada. Scleroderma Overview. Available at https://fhs.mcmaster.ca/purr/documents/Scleroderma-Overview.pdf 10 Ofev® Product Monograph. Boehringer Ingelheim (Canada) Ltd. November 21, 2019. 11 Canadian Pulmonary Fibrosis Foundation. Understanding PF – What is Pulmonary Fibrosis? Available at https://cpff.ca/understanding-pf/what-is-pulmonary-fibrosis/ 12 Distler O, et al. Nintedanib for Systemic Sclerosis – Associated Interstitial Lung Disease. New England Journal of Medicine. 2019; 1-11. 13 Distler O, et al. Nintedanib for Systemic Sclerosis – Associated Interstitial Lung Disease. New England Journal of Medicine. 2019; 1-11. 14 Ofev® Product Monograph. Boehringer Ingelheim (Canada) Ltd. November 21, 2019.
SOURCE Boehringer Ingelheim (Canada) Ltd.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
